_icll07-filo-study-minimal-residual-disease-still-detectable-after-first-line-combination-therapy.jpg "ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy from umrd Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 20 sec
✓ Published: 17-Jun-2018
✓ Published: 17-Jun-2018
Description:
Prof Feugier speaks with ecancer at EHA 23 about results from a phase II trial of treating CLL with induction obinutuzumab and ibrutinib.nnHe describes how CR with undetectable residual disease (uMRD) may be associated with a longer survival in CLL.nnWith a manageable toxicity profile, 48% CR rate and 12.5% uMRD at 9 months, Prof Feugier describes the need for further research and further rounds of immunochemotherapy to fully induce uMRD.
Prof Feugier speaks with ecancer at EHA 23 about results from a phase II trial of treating CLL with induction obinutuzumab and ibrutinib.nnHe describes how CR with undetectable residual disease (uMRD) may be associated with a longer survival in CLL.nnWith a manageable toxicity profile, 48% CR rate and 12.5% uMRD at 9 months, Prof Feugier describes the need for further research and further rounds of immunochemotherapy to fully induce uMRD.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_undetectable-minimal-residual-disease-umrd-explained.webp "Dr. Brian Koffman, co-founder of The CLL Society, defines the term undetectable minimal residual disease (UMRD) and explains its role in chronic lymphocytic leukemia (CLL) care.nnDr. Brian Koffman is the cofounder, chief medical officer, and executive vice president of The CLL Society.")
_undetectable-minimal-residual-disease-umrd-explained.webp "Patient Empowerment Network")
_captivate-study-outcomes-in-patients-with-umrd-following-cessation-of-ibrutinib-plus-venetoclax.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 34 seconds 👁 49
_captivate-ibrutinib-venetoclax-delivers-high-rates-of-umrd-in-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_liso-cel-induces-rapid-umrd-transcend-cll-004-update.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_glow-study-mrd-outcomes-after-fixed-duration-ibrven-versus-clbo-for-first-line-treatment-of-cll-in-elderly-or-unfit-pati.webp "Dr Arnon Kater speaks to ecancer about the Glow study. nnThis is the first prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients. nnInitially, he explains the background of the Glow study. nnDr Kater then discusses the methods and key results. All-oral, once-daily, fixed-duration Ibr+Ven demonstrated superior uMRD responses that")
⏲ 3 min 48 sec ✓ 14-Dec-2021
_mrd-guided-acalabrutinib-venetoclax-and-obinutuzumab-therapy-for-cll-ash-2023.webp "CLL Society")
⏲ 10 minutes 21 seconds 👁 125
_undetectable-minimal-residual-disease-umrd-explained.jpg)
_undetectable-minimal-residual-disease-umrd-explained.jpg)
_captivate-study-outcomes-in-patients-with-umrd-following-cessation-of-ibrutinib-plus-venetoclax.jpg)
_captivate-ibrutinib-venetoclax-delivers-high-rates-of-umrd-in-cll.jpg)
_liso-cel-induces-rapid-umrd-transcend-cll-004-update.jpg)
_glow-study-mrd-outcomes-after-fixed-duration-ibrven-versus-clbo-for-first-line-treatment-of-cll-in-elderly-or-unfit-pati.jpg)
_mrd-guided-acalabrutinib-venetoclax-and-obinutuzumab-therapy-for-cll-ash-2023.jpg)
![[+]](/images/menu.gif){kind=small}